Sermorelin is a fragment of growth hormone-releasing hormone. Instead of injecting growth hormone, it signals the pituitary to release its own, preserving the pulses and feedback loops that direct GH replacement bypasses. The evidence for downstream benefit in healthy aging adults is limited, and the honest reading of the GH-and-aging literature is negative.
Longevity
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
Growth hormone release is governed by two hypothalamic signals in opposition: GHRH, which stimulates the somatotroph cells of the anterior pituitary to release GH, and somatostatin, which suppresses them. The interplay produces the pulsatile secretion pattern that characterises normal GH physiology, with most output occurring in bursts, heavily weighted toward the night.
Sermorelin is GHRH(1-29) amide, the truncated form retaining full activity at the GHRH receptor.1 Given by subcutaneous injection, usually at night, it prompts a pituitary GH pulse.
The design argument is straightforward. Injecting recombinant growth hormone creates a sustained, non-physiological elevation that overrides the body's own regulation and suppresses endogenous production through negative feedback. A GHRH analog works one step upstream: the pituitary still releases GH in pulses, somatostatin still restrains it, and IGF-1 feedback still applies. The system's brakes remain connected.1
That has a practical consequence. A secretagogue cannot easily push GH beyond what the pituitary is capable of releasing, because the feedback loop limits it. That built-in ceiling is a safety feature relative to exogenous GH, and it is also a limit on how large an effect it can produce. It requires a pituitary that still works, which is why sermorelin is not a treatment for structural pituitary failure.
Growth hormone output falls steadily from early adulthood. The decline, sometimes labelled somatopause, is driven mainly by reduced GHRH signalling and increased somatostatin tone rather than by loss of pituitary capacity. The somatotrophs largely remain able to respond; they are being asked less often and restrained more.
That distinction is the pharmacological opening for sermorelin. If the deficit is in the signal rather than the machinery, supplying signal is a more physiological correction than supplying product.1 The review that popularised sermorelin as an approach to adult-onset growth hormone insufficiency makes exactly this argument, and the argument is coherent.1
Coherent is not the same as demonstrated. The lower GH output of an older adult is not obviously pathological. It may be an adaptation, and the epidemiology of GH and IGF-1 signalling in longevity research is genuinely mixed, with reduced signalling associated with longer lifespan in several model organisms and in some human cohorts. Anyone presenting age-related GH decline as an unambiguous deficiency to be corrected is skipping over a live scientific argument.
The largest GH pulse of the day occurs shortly after sleep onset, tied to slow-wave sleep. The relationship runs in both directions: deep sleep drives GH release, and GHRH signalling appears to promote deep sleep.
A controlled human study found that growth hormone-releasing hormone enhanced non-rapid-eye-movement sleep after sleep deprivation.2 This is human data, which is scarcer in this field than it should be, and it supports a modest, specific claim: GHRH signalling influences sleep architecture in people.
It supports that and no more. It is a small mechanistic study in a controlled sleep-laboratory setting after experimental sleep deprivation. It is not a trial of sermorelin for insomnia or for sleep quality in ordinary life, and no such trial establishes that. Anyone reading a nightly sermorelin injection as a sleep treatment is extending this result well past what it measured.
IGF-1 is the standard downstream marker for GH activity, produced largely by the liver in response to GH and more stable in blood than GH itself, which makes it the practical thing to measure.
A study of growth hormone secretagogue treatment in hypogonadal men reported raised serum IGF-1 levels.3 That is a real human result and it confirms the mechanism does what it claims: the signal reaches the pituitary, GH is released, and the liver responds.
Read the study design honestly. It was small, it was in a specific population of hypogonadal men, and its endpoint was a biomarker. Raising IGF-1 is proof of pharmacological action, not proof of clinical benefit. Body composition, strength, energy, sleep quality, and recovery are the outcomes people actually want, and the trial evidence for sermorelin on those endpoints in healthy aging adults is thin to absent.
That is the state of the field, stated plainly. The mechanism is well characterised, the biomarker moves, and the outcome trials that would justify strong claims have not been run at scale.
The broader question sitting behind every GH-adjacent therapy is whether raising growth hormone activity slows or reverses aging. That question has been examined directly, and we are going to present the conclusion without softening it.
A review of growth hormone, menopause and ageing concluded that there is no definite evidence for rejuvenation with growth hormone.4 Not insufficient evidence pending better trials, phrased as a promissory note. The literature was reviewed and the rejuvenation claim was not supported.
That conclusion concerns growth hormone itself, which is the strongest possible test of the idea, since exogenous GH raises GH activity far more than any secretagogue can. If maximal GH elevation does not produce rejuvenation, a pituitary signal operating within feedback limits is not going to do so either.
The reasonable position that survives this: sermorelin is a physiologically sensible way to support GH signalling in adults with a documented reason to want that, prescribed and monitored, with IGF-1 tracked. It is not an anti-aging treatment, and the evidence does not permit describing it as one.
Compounded sermorelin is prepared for an individual patient by a state-licensed US compounding pharmacy on a physician's prescription and is not an FDA-approved product. Evaluation should include IGF-1 measurement and a real conversation about what the data supports, which is less than the marketing around this category generally claims.
The mechanistic argument for sermorelin over growth hormone is genuinely good. The clinical argument that either one reverses aging is not, and the second does not inherit credibility from the first.
Astra Editorial
Sermorelin is a GHRH analog that prompts your own pituitary to release growth hormone in pulses, keeping negative feedback intact. Injected growth hormone bypasses that regulation and suppresses your own production.
No. A review of growth hormone, menopause and ageing concluded there is no definite evidence of rejuvenation with growth hormone, which is a stronger intervention than a secretagogue.
GHRH enhanced non-REM sleep in a controlled human study after sleep deprivation. That is a mechanistic finding in a sleep laboratory, not a trial of sermorelin as a sleep treatment.
No. It is prepared for an individual patient by a state-licensed US compounding pharmacy on a physician's prescription. Compounded preparations are not FDA-approved products.
Compounded sermorelin — online evaluation. Only charged if prescribed. Astra's program is prescribed and supervised by a licensed physician and dispensed by a state-licensed US compounding pharmacy, with IGF-1 monitoring as part of the plan. From $120/mo.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.